Search Results

You are looking at 41 - 50 of 460 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Christopher A. Barker and April K. Salama

also noted that immunotherapies that are robust in the advanced disease setting are now proving their worth as adjuvant treatment. Several effective options are now approved for adjuvant therapy besides observation. Nivolumab is now preferred over

Full access

Michael D. Green and James A. Hayman

the primary site . JAMA Dermatol 2016 ; 152 : 1001 – 1007 . 21. Fields RC Busam KJ Chou JF . Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma . Cancer 2012 ; 118

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

– 14 Thus, in these high-risk patients, it would seem reasonable to offer SLNB to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. NCCN Guidelines Insights : Metastatic Colon Cancer, Version

Full access

Stephanie L. Lee

Effects of 131 I Therapy RAI therapy is given either as remnant ablation (the most common use), adjuvant therapy, or treatment of metastatic disease. Remnant ablation uses RAI to destroy normal residual functioning thyroid tissues with the goals

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

Biol Endocrinol 2011 ; 9 : 93 . 9. Eggemann H Ignatov A Smith BJ . Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients . Breast Cancer Res Treat 2013 ; 137 : 465 – 470 . 10

Full access

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

and 193). 1 – 5 However, for some patients with early-stage disease, surgery alone (followed by observation) may be sufficient as primary treatment. In addition, for certain histologic subtypes, adjuvant therapy with hormonal agents are options that

Full access

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

are generally managed surgically, and patients with tumors harboring high-risk features are recommended to receive adjuvant therapy with imatinib, a tyrosine kinase inhibitor that targets the KIT and PDGFRA oncoproteins, but not BRAF, NTRK3, or FGFR1

Full access

Nadeem R. Abu-Rustum and Yukio Sonoda

-sparing adjuvant therapy in patients with node-positive disease. The authors' current selection criteria for fertility-sparing radical trachelectomy are listed in Table 1 . Patients are selected for a laparoscopic vaginal approach (Dargent operation) if they are

Full access

Elizabeth Reed, Robin M. Lally, and Roksana Zak

unavailable (n=66). Eight clinical pathways based on ER, PR, and HER2 status were developed to guide treatment, considerations, evidence-based neoadjuvant and adjuvant therapy, and survivorship care. Pathways, with associated educational webinars and links to

Full access

Heidi Klepin, Supriya Mohile, and Arti Hurria

/CTSU 49907 [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 507 . 31 Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19